Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GS-2426 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Phase 1a: Monotherapy Dose Escalation | EXPERIMENTAL | Participants will receive escalating doses of GS-2426 monotherapy, until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol, or up to a maximum of 105 week, whichever occurs first. |
| Phase 1b: Monotherapy Dose Expansion | EXPERIMENTAL | Participants will be enrolled in different indication-specific cohorts. Participants will receive GS-2426 monotherapy at the recommended dose until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol, or up to a maximum of 105 weeks, whichever occurs first. |
| Name | Type | Description |
|---|---|---|
| GS-2426 | DRUG | Administered Orally |
Key Inclusion Criteria: * Participants 18 years of age or older (≥ 19 years old for participants in South Korea). * Histologically or cytologically confirmed advanced malignant solid tumors, who have progressed on, are intolerant to or are ineligible for standard therapy, or have no standard treatm...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
GS-2426 is an investigational small molecule being developed for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and efficacy in patients.
GS-2426 is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The company is conducting a Phase 1 clinical trial to evaluate the drug in patients with advanced solid tumors.
GS-2426 is in Phase 1 clinical development. It is an investigational drug, not yet approved by the FDA or any other regulatory agency. The ongoing Phase 1 trial is actively recruiting participants with advanced solid tumors in the United States.
GS-2426 is being studied in a single Phase 1 clinical trial with the identifier NCT07601243, titled "Study of GS-2426 in Participants With Advanced Solid Tumors." The trial is currently recruiting and aims to enroll 174 participants aged 18 years and older in the United States.
No alternative names for GS-2426 have been disclosed. It is identified solely by its investigational code name GS-2426 in clinical trial registrations and by the developer, Gilead Sciences.